Tigermed (300347.SZ/3347.HK), a prominent global Contract Research Organization (CRO) offering comprehensive research and development solutions for the biopharmaceutical and medical device sectors, has officially inaugurated its International Headquarters in Hong Kong. This significant step highlights the company's commitment to global operations and corporate advancement.

The establishment of the International Headquarters in Hong Kong will enhance Tigermed's ability to efficiently manage and coordinate global projects, facilitate business expansion, and provide its services to customers on a global scale. This move will inject fresh momentum into various aspects of the company, including its service platform, global talent, supporting functions, and corporate culture.

Tigermed's presence in Hong Kong dates back to 2011 when it established its office there. Over the past decade, the company has collaborated with local researchers and clinical sites to advance innovative product development. Tigermed's listing on the Hong Kong Stock Exchange (HKSE) in August 2020 further solidified its foothold in the region. The establishment of the International Headquarters in Hong Kong underscores its dedication to expanding research capabilities and extending global reach to create a comprehensive service platform.

Hong Kong, a prominent financial hub in the Asia-Pacific region, holds a significant position in the global healthcare sector due to its competitive business environment and culture of innovation. With support from the Hong Kong Innovation, Technology, and Industry Bureau (ITIB), the Office for Attracting Strategic Enterprises (OASES), and various stakeholders, Tigermed's International Headquarters was efficiently established and is now poised to make a meaningful impact on the clinical development landscape in the region.

Looking ahead, Tigermed aims to collaborate with global innovative enterprises and research institutions, offering high-quality CRO services for the pharmaceutical and medical device industries. Leveraging its extensive project experience and advanced technology platform, Tigermed strives to attract innovative projects on a global scale, contributing to the establishment of a robust R&D system.

Dr. Xiaoping Ye, Co-Founder and Chairman of Tigermed, emphasized the company's dedication to global expansion: "As a leading contract service provider, global development has always been a crucial part of our corporate strategy. With the International Headquarters going into operation, we will continue strengthening the global presence and leveraging our unique global layout to enhance service offerings and connections with partners worldwide. We aim to serve as a bridge to advance healthcare breakthroughs for patients."

About Tigermed

Tigermed (Stock code: 300347.SZ/3347.HK) is a preeminent global provider of integrated research and development solutions for the biopharmaceutical and medical device industries. With a comprehensive range of services and a commitment to quality, Tigermed supports customers throughout their development journey from preclinical stages to clinical trials and commercialization. The company's extensive network comprises over 100 subsidiaries and 180 service locations worldwide, with a workforce of over 10,000 employees across 50 countries. Tigermed's dedication to building an integrated platform aims to revolutionize the healthcare industry, address unmet patient needs, and ultimately save lives.

Report Abuse